{"schema_version":"secwatch.filing_event.v1","accession":"0000896264-24-000180","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2024-07-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.228416+00:00","generated_at":"2026-05-31T18:22:59.917640+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"USANA Q2 net sales $213M (-11% YoY), EPS $0.54 (-39%); cuts FY2024 guidance","bullets":["Diluted EPS $0.54 vs. $0.89 in Q2 2023; net sales $213M down 11% YoY to $238M.","Active customers fell 4% YoY to 468,000; macro pressures and fewer promotions cited.","FY24 outlook: net sales $850-880M (prev $850-920M), EPS $2.40-2.55 (prev $2.40-3.00).","Operating margin revised to 8.0%-8.8%; effective tax rate raised to 43%-44%.","Cash $332M, no debt; no share repurchases in Q2; $62M authorization remaining."],"urls":{"canonical":"https://secwatch.observer/filing/0000896264-24-000180","json":"https://secwatch.observer/filing/0000896264-24-000180.json","markdown":"https://secwatch.observer/filing/0000896264-24-000180.md","text":"https://secwatch.observer/filing/0000896264-24-000180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000089626424000180/0000896264-24-000180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000089626424000180/usna-20240723.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T18:22:59.917640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}